🔗 Share this article

The initial novel therapies for gonorrhoea in a generation are being hailed as a "huge turning point" in the battle against increasingly resistant strains of the infection, according to scientists.

An International Challenge

The sexually transmitted infection are on the rise globally, with figures suggesting in excess of 82 million infections per year. Especially elevated rates are observed in Africa and nations within the WHO's designated area, which encompasses China and Mongolia to New Zealand. Within England, cases have hit a record high, while figures across Europe in 2023 were significantly elevated compared to the rates from 2014.

“The authorization of novel therapies for gonorrhoea is an critical and opportune step in the context of increasing worldwide cases, the spread of superbugs and the very limited available drugs presently on offer.”

Health officials are particularly alarmed about the rise in treatment-resistant strains. The global health body has listed it as a "high-priority threat". A tracking program showed that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Treatment Options Receive Approval

One new antibiotic, marketed under the name a brand name, was authorized by the American regulatory agency in recent days for use against gonorrhoea. This STI can lead to major issues, including infertility. Researchers believe that specific application of this new drug will help slow the spread of drug resistance.

Another new antibiotic, created by the pharmaceutical company GlaxoSmithKline, also received approval in concurrent days. This drug, which is also used to treat UTIs, was shown in trials to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Partnership

This new treatment emerged from a unique collaborative effort for medication research. The charitable organization GARDP collaborated with the drug firm its industry partner to bring it to fruition.

“This milestone signifies a major breakthrough in the management of superbug gonorrhoea, which up to this point has been evolving faster than antibiotic development.”

Research Study Results and Worldwide Availability

According to results published in a major medical journal, zoliflodacin cured the vast majority of genital gonorrhoea infections. This places it at an comparable level with the existing first-line therapy, which uses a dual-drug approach. The trial involved nearly 1,000 participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the rights to register and commercialise the drug in numerous low-income and middle-income countries.

Medical professionals on the front lines have voiced optimism. The availability of a one-pill regimen such as this is described as a "revolutionary step" for public health efforts. This is deemed vital to alleviate the strain of the infection for people and to halt the transmission of highly drug-resistant gonorrhoea worldwide.